Indeed, GnRH agonist injection prevents the suboptimal compliance of oral progestin treatment and does not increase the risk of thrombophlebitis, change in lipid metabolism, atherogenesis, or other diseases such as diabetes, hypertension, or hyperlipoproteinemia (37, 38). This evidence concerns the gene GNRH1 and hypertensive disorder.